Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nisheet Prasad

Rheumatology Jamesburg, NJ Medical Doctor

NPI 1144258856 CMS profile 279164

100 Lakeview Dr Ste 2, Jamesburg, NJ 08831

Open in the dashboard

General payments

$7,084

374 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nisheet Prasad of Jamesburg, NJ is reported in the CMS Open Payments database as having received $7,084 across 374 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,675 87
2024 General $1,580 76
2023 General $1,699 89
2022 General $914 63
2021 General $561 38
2020 General $184 7
2019 General $472 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nisheet Prasad
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Nisheet Prasad were reported at $1,675. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Nisheet Prasad Rheumatology median Middle half National median
2019 $472 $744 $153–$2,687 $163
2020 $184 $462 $98–$2,027 $114
2021 $561 $531 $101–$2,153 $132
2022 $914 $627 $125–$2,303 $149
2023 $1,699 $741 $145–$2,524 $160
2024 $1,580 $830 $166–$2,660 $164
2025 $1,675 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,995 98 payments
  2. Amgen Inc. $1,018 65 payments
  3. Janssen Biotech, Inc. $886 44 payments
  4. GlaxoSmithKline, LLC. $759 43 payments
  5. Amneal Pharmaceuticals LLC $575 31 payments
  6. AstraZeneca Pharmaceuticals LP $412 16 payments
  7. Novartis Pharmaceuticals Corporation $248 9 payments
  8. Lilly USA, LLC $202 15 payments
  9. Horizon Therapeutics plc $194 4 payments
  10. Pharmacosmos Therapeutics Inc. $101 1 payment
  11. Other $697 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,814 369 payments
  2. Education $270 5 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,871 89 payments
  2. TREMFYA $879 43 payments
  3. BENLYSTA $735 41 payments
  4. UNITHROID $575 31 payments
  5. Otezla $471 26 payments
  6. Enbrel $448 39 payments
  7. SAPHNELO $387 14 payments
  8. TAVNEOS $235 10 payments
  9. KRYSTEXXA $194 4 payments
  10. SIMPONI ARIA $191 6 payments
  11. Other $1,768 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,906

Median for Rheumatology: 1,511

Drug cost

$607,801

Median for Rheumatology: $1,139,948

Branded share of claims

22.8%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xeljanz Xr Tofacitinib Citrate Brand 34 $189,351
Humira(Cf) Pen Adalimumab Brand 17 $179,851
Enbrel Sureclick Etanercept Brand 23 $171,746
Prolia Denosumab Brand 13 $22,344
Hydroxychloroquine Sulfate Generic 459 $18,081
Methotrexate Methotrexate Sodium Brand 327 $9,758
Leflunomide Generic 79 $3,989
Prednisone Generic 405 $2,525
Mycophenolate Mofetil Generic 28 $2,246
Colchicine Generic 24 $1,031

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$290,432

Of which drugs: $111,167

Medicare patients

340

Average age 73

Services billed

16,170

229 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 46%
Ischemic heart disease 33%
Osteoporosis 31%
Depression 27%
Chronic kidney disease 26%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 20 1,620 $33,889
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg J7320 Office 21 2,386 $10,392
Injection, methylprednisolone acetate, 1 mg J1010 Office 37 3,496 $344

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $536
$536 — —
TREMFYA
  • Janssen Biotech, Inc. $301
$301 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $189
$189 — —
UNITHROID
  • Amneal Pharmaceuticals LLC $188
$188 — —
Enbrel
  • Amgen Inc. $143
$143 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

374 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record